<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02648932</url>
  </required_header>
  <id_info>
    <org_study_id>IRB15-0866</org_study_id>
    <nct_id>NCT02648932</nct_id>
  </id_info>
  <brief_title>The Rapid Study: Randomized Phase II Study To Expedite Allogeneic Transplant With Immediate Haploidentical Plus Unrelated Cord Donor Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients</brief_title>
  <official_title>The Rapid Study: Randomized (RA) Phase (P) II Study To Expedite Allogeneic Transplant With Immediate (I) Haploidentical Plus Unrelated Cord Donor (D) Search Versus Matched Unrelated Donor Search For AML And High-Risk MDS Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to compare time from formal search to hematopoietic cell transplantation&#xD;
      (HCT) for patients 18 years and older, randomized between haplo-cord search and matched&#xD;
      unrelated donor (MUD) search for patients with acute myeloid leukemia (AML) and high-risk&#xD;
      myelodysplastic syndrome (MDS)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives&#xD;
&#xD;
      To compare time from formal search to hematopoietic cell transplantation (HCT) for patients&#xD;
      18 years and older, randomized between haplo-cord search and matched unrelated donor (MUD)&#xD;
      search for patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome&#xD;
      (MDS)&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        -  To compare the percentage of patients who undergo HCT in each study cohort&#xD;
&#xD;
        -  To evaluate overall survival from time to randomization by study cohort&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual&#xD;
  </why_stopped>
  <start_date type="Actual">February 4, 2016</start_date>
  <completion_date type="Actual">April 2020</completion_date>
  <primary_completion_date type="Actual">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Transplant</measure>
    <time_frame>Through one year after formal search</time_frame>
    <description>Time to transplant will be measured from time of date of formal request to stem cell infusion date. Will also capture time from preliminary search to both formal search and transplant date.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Undergo Hematopoietic Cell Transplantation (HCT)</measure>
    <time_frame>Through one year after formal search</time_frame>
    <description>Compare percentage of patients who undergo HCT in each study cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Survival Time</measure>
    <time_frame>From date of randomization up to 3 years</time_frame>
    <description>Overall survival time was estimated from date of randomization and from date of transplant using Kaplan-Meier method.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Acute Myeloid Leukemia (AML)</condition>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>Haplo-Cord Search</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched Unrelated Donor Search (MUD)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If subject meets the inclusion criteria and consents, will undergo a MUD transplant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Haplo-Cord Transplant</intervention_name>
    <description>For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device</description>
    <arm_group_label>Haplo-Cord Search</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Matched Unrelated Donor Transplant</intervention_name>
    <arm_group_label>Matched Unrelated Donor Search (MUD)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria for Search Phase:&#xD;
&#xD;
          1. Diagnosis of acute myeloid leukemia (AML) or high or very high-risk MDS by&#xD;
             international prognostic scoring system revised for whom transplant is recommended&#xD;
&#xD;
          2. 18 years of age or older&#xD;
&#xD;
          3. Subject is likely to be considered for allogeneic transplant in the opinion of the&#xD;
             transplant physician (based on age of patient, health, cytogenetics, and/or molecular&#xD;
             characteristics).&#xD;
&#xD;
          4. Karnofsky Performance Status (KPS) &gt;/= 70% at time of enrollment. An exception will be&#xD;
             made for those with lower KPS at enrollment with an acute worsening that is likely to&#xD;
             resolve in the treating physicians judgment (e.g., reversible infection,trauma,&#xD;
             medication reaction, etc)&#xD;
&#xD;
          5. Ability to understand and the willingness to sign a written informed consent document&#xD;
             for the Search Phase.&#xD;
&#xD;
          6. Patient willing to consider HCT&#xD;
&#xD;
          7. A preliminary search has identified:&#xD;
&#xD;
               1. An appropriate minimum 4/6 matched umbilical cord unit at intermediate resolution&#xD;
                  at HLA-A and B, and high resolution at HLA-DRB with a cell dose above 1 x 10(7)&#xD;
                  TNC/kg for a single umbilical cord blood (UCB) transplant AND&#xD;
&#xD;
               2. At least one potential 8/8 HLA-matched (HLA-A, -B, -C, and -DRB1) unrelated donor&#xD;
                  with a probability of 70% AND&#xD;
&#xD;
               3. Availability of a potential related haploidentical donor.&#xD;
&#xD;
        Exclusion Criteria for Search Phase:&#xD;
&#xD;
          1. Prior formal search was instituted&#xD;
&#xD;
          2. Diagnosis of acute promyelocytic leukemia (APL)&#xD;
&#xD;
          3. Known HLA matched related donor without contraindications to donate&#xD;
&#xD;
          4. Life expectancy severely limited by concomitant illness or uncontrolled infection&#xD;
&#xD;
        Inclusion Criteria for Transplant Phase&#xD;
&#xD;
          1. High-risk AML for which transplant is recommend based on cytogenetic, molecular and&#xD;
             morphologic features. Patients must meet institutional standards for disease control&#xD;
             prior to transplant.&#xD;
&#xD;
          2. For MDS. IPSS-revised criteria of high or very high at diagnosis.&#xD;
&#xD;
          3. Subject meets institutional criteria for transplant and has acceptable organ and&#xD;
             marrow function as defined below:&#xD;
&#xD;
               1. Serum bilirubin &lt; 2.0mg/dL unless Gilberts disease&#xD;
&#xD;
               2. Creatinine Clearance &gt; 45 mL/min.1.73m2 as estimated by modified MDRD equation&#xD;
&#xD;
               3. Left ventricular function 40% or greater&#xD;
&#xD;
               4. DLCO corrected for hemoglobin &gt;50%&#xD;
&#xD;
               5. KPS 70% or greater&#xD;
&#xD;
          4. An adequate graft for the defined donor type&#xD;
&#xD;
               1. Haplo-cord requires a haploidentical adult donor of 14 years of age and at least&#xD;
                  50 kg, and a cord blood unit with at least 1.0 x 10(7) TNC/kg and a match of at&#xD;
                  least 4/6 by intermediate resolution for HLA-A and B and high resolution at DRB1.&#xD;
                  Donor provides standard of care consent for harvest following institutional&#xD;
                  policy. Any donor samples or donor research data would be obtained on separate&#xD;
                  donor research protocol.&#xD;
&#xD;
               2. For MUD requires a 7/8 or 8/8 HLA matched unrelated donor with high resolution&#xD;
                  matching at HLA-A, -B, -C, and DRB1. DP matching or DP permissive should be&#xD;
                  achieved when possible using T-cell epitope strategy.&#xD;
&#xD;
          5. Written informed consent for the transplant phase&#xD;
&#xD;
        Exclusion Criteria for Transplant Phase&#xD;
&#xD;
          1. Life expectancy severely limited by concomitant illness or uncontrolled infection&#xD;
&#xD;
          2. HIV-positive&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Artz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago Cancer Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 4, 2016</study_first_submitted>
  <study_first_submitted_qc>January 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2016</study_first_posted>
  <results_first_submitted>February 22, 2021</results_first_submitted>
  <results_first_submitted_qc>February 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 18, 2021</results_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia (AML)</keyword>
  <keyword>High-Risk Myelodysplastic Syndrome (MDS)</keyword>
  <keyword>hematopoietic cell transplantation</keyword>
  <keyword>haplo-cord search</keyword>
  <keyword>matched unrelated donor search</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT02648932/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Haplo-Cord Search</title>
          <description>If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.&#xD;
Haplo-Cord Transplant: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device</description>
        </group>
        <group group_id="P2">
          <title>Matched Unrelated Donor Search (MUD)</title>
          <description>If subject meets the inclusion criteria and consents, will undergo a MUD transplant.&#xD;
Matched Unrelated Donor Transplant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No transplant</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Haplo-Cord Search</title>
          <description>If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.&#xD;
Haplo-Cord Transplant: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device</description>
        </group>
        <group group_id="B2">
          <title>Matched Unrelated Donor Search (MUD)</title>
          <description>If subject meets the inclusion criteria and consents, will undergo a MUD transplant.&#xD;
Matched Unrelated Donor Transplant</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.9" lower_limit="53.5" upper_limit="71.9"/>
                    <measurement group_id="B2" value="61.2" lower_limit="53" upper_limit="66.8"/>
                    <measurement group_id="B3" value="62.1" lower_limit="53" upper_limit="71.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to Transplant</title>
        <description>Time to transplant will be measured from time of date of formal request to stem cell infusion date. Will also capture time from preliminary search to both formal search and transplant date.</description>
        <time_frame>Through one year after formal search</time_frame>
        <population>We analyze only those who went to transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo-Cord Search</title>
            <description>If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.&#xD;
Haplo-Cord Transplant: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device</description>
          </group>
          <group group_id="O2">
            <title>Matched Unrelated Donor Search (MUD)</title>
            <description>If subject meets the inclusion criteria and consents, will undergo a MUD transplant.&#xD;
Matched Unrelated Donor Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Transplant</title>
          <description>Time to transplant will be measured from time of date of formal request to stem cell infusion date. Will also capture time from preliminary search to both formal search and transplant date.</description>
          <population>We analyze only those who went to transplant.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69" lower_limit="63" upper_limit="74"/>
                    <measurement group_id="O2" value="111" lower_limit="68" upper_limit="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Undergo Hematopoietic Cell Transplantation (HCT)</title>
        <description>Compare percentage of patients who undergo HCT in each study cohort</description>
        <time_frame>Through one year after formal search</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Haplo-Cord Search</title>
            <description>If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.&#xD;
Haplo-Cord Transplant: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device</description>
          </group>
          <group group_id="O2">
            <title>Matched Unrelated Donor Search (MUD)</title>
            <description>If subject meets the inclusion criteria and consents, will undergo a MUD transplant.&#xD;
Matched Unrelated Donor Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Undergo Hematopoietic Cell Transplantation (HCT)</title>
          <description>Compare percentage of patients who undergo HCT in each study cohort</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Survival Time</title>
        <description>Overall survival time was estimated from date of randomization and from date of transplant using Kaplan-Meier method.</description>
        <time_frame>From date of randomization up to 3 years</time_frame>
        <population>We analyzed only those who went transplant.</population>
        <group_list>
          <group group_id="O1">
            <title>Haplo-Cord Search</title>
            <description>If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.&#xD;
Haplo-Cord Transplant: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device</description>
          </group>
          <group group_id="O2">
            <title>Matched Unrelated Donor Search (MUD)</title>
            <description>If subject meets the inclusion criteria and consents, will undergo a MUD transplant.&#xD;
Matched Unrelated Donor Transplant</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Survival Time</title>
          <description>Overall survival time was estimated from date of randomization and from date of transplant using Kaplan-Meier method.</description>
          <population>We analyzed only those who went transplant.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days from randomization</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162" lower_limit="162" upper_limit="NA">There are not enough people have died yet to estimate the upper confidence interval. One of two participants survived.</measurement>
                    <measurement group_id="O2" value="785" lower_limit="607" upper_limit="NA">There are not enough people have died yet to estimate the upper confidence interval. One of three participants survived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days from transplant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" lower_limit="92" upper_limit="NA">There are not enough people have died yet to estimate the upper confidence interval. One of two participants survived.</measurement>
                    <measurement group_id="O2" value="673" lower_limit="467" upper_limit="NA">There are not enough people have died yet to estimate the upper confidence interval. One of three participants survived.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>100 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Haplo-Cord Search</title>
          <description>If subject meets the inclusion criteria and consents, will undergo a haplo-cord transplant.&#xD;
Haplo-Cord Transplant: For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device</description>
        </group>
        <group group_id="E2">
          <title>Matched Unrelated Donor Search (MUD)</title>
          <description>If subject meets the inclusion criteria and consents, will undergo a MUD transplant.&#xD;
Matched Unrelated Donor Transplant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hongtao Liu</name_or_title>
      <organization>University of Chicago</organization>
      <phone>773-834-0589</phone>
      <email>hliu2@medicine.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

